CN105535227A - Medicine composition for treating middle and advanced pancreatic cancer - Google Patents

Medicine composition for treating middle and advanced pancreatic cancer Download PDF

Info

Publication number
CN105535227A
CN105535227A CN201610047066.5A CN201610047066A CN105535227A CN 105535227 A CN105535227 A CN 105535227A CN 201610047066 A CN201610047066 A CN 201610047066A CN 105535227 A CN105535227 A CN 105535227A
Authority
CN
China
Prior art keywords
pharmaceutical composition
weight portion
ethanol
percent concentration
pancreatic cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN201610047066.5A
Other languages
Chinese (zh)
Inventor
不公告发明人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jinan Xingyi Medical Technology Co Ltd
Original Assignee
Jinan Xingyi Medical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jinan Xingyi Medical Technology Co Ltd filed Critical Jinan Xingyi Medical Technology Co Ltd
Priority to CN201610047066.5A priority Critical patent/CN105535227A/en
Publication of CN105535227A publication Critical patent/CN105535227A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/80—Scrophulariaceae (Figwort family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
    • A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/50—Methods involving additional extraction steps
    • A61K2236/55—Liquid-liquid separation; Phase separation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicinal Preparation (AREA)

Abstract

The invention discloses a medicine composition for treating a middle and advanced pancreatic cancer and a preparation method thereof. The medicine composition is prepared from papiliochrome II, Mazus stachydifolius and Bergia ammanioides Roxb. in a matching mode. Various dosage forms can be prepared according to a normal formulation technology, and the medicine composition has the remarkable effect on treating the middle and advanced pancreatic cancer.

Description

The pharmaceutical composition for the treatment of advanced pancreatic cancer
Technical field
The invention belongs to technical field of Chinese medicines, particularly relate to a kind of pharmaceutical composition for the treatment of advanced pancreatic cancer and preparation method thereof.
Background technology
Cancer of pancreas is the high digestive system tumor of a kind of grade malignancy, and the sickness rate of recent domestic cancer of pancreas is all in obviously increasing trend.Cancer of pancreas onset is hidden, less specific symptom and sign, and only the Pancreas cancer patients of <20% has excision chance, Postoperative recurrent rate and the rate of transform high, occupying Death Causes of Tumor the 4th, is one of very poor malignant tumor of prognosis.Owing to reaching middle and advanced stage when a lot of patient makes a definite diagnosis, therefore actively inquire into new therapeutic scheme to controlling tumour progression, the quality of life of particularly improving patient has important value.
Cancer of pancreas is a kind of disease making people's exhaustion gradually, improves the outstanding tool importance of symptom.US National Cancer center (NCI) and FDA have admitted and have improved the valuable target that tumor-related symptoms itself is also Current cancer treatment.Due to the clinical symptoms of tumor and the size of tumor load directly related, therefore tumor load reduce very little part clinical symptoms can be made to obtain larger improvement.Some researchs also show that the change of chemotherapeutic period CA19-9 level can be used as monitoring cancer of pancreas curative effect and the important indicator judging its prognosis.
Papiliochrome II(PapiliochromeII): CAS 68335-21-7, molecular formula C 21h 26n 4o 6, molecular weight 430.46.
Herba mazi stachydifolii: this product is Scrophulariaceae Mazus plant Herba mazi stachydifolii Mazusstachydifolius(Turcz.) herb of Maxim..Gather when yielding positive results, dry.[nature and flavor] taste is micro-pungent; Cool in nature.[function cures mainly] heat-clearing and toxic substances removing; Cool the blood dissipate blood stasis.Main constipation hematochezia; Furuncle toxic swelling; Venom; Traumatic injury.[original shape state] perennial herb, high 10-50cm.Sturdy, Herb is by the long pubescence of white.Root stock is short; Stem is upright, and rare rising is cylindrical, not branch or base portion branch, base portion lignifying time old.Basal leaf cochlear, has short handle, normal early withered; Stem leaf to life, the normal alternate on top, stockless; Blade oblong is to the shape of falling ovum lanceolar; Papery, long 2-7cm, large with the amount in the middle part of stem, edge tool sawtooth.Raceme top is raw, and long 2-20cm, spends sparse; Bract triangle; Calyx funnel-form, long 0.5-1cm, longer than bennet, calyx tooth is slightly longer than a portion, the long sharp point of tip; Corolla is purple with, long 1.5-2cm; Tube and lip are closely isometric, and upper lip is short, and 2 split, sliver long-narrow triangular mesh, end point, and lower lip is roomy, carries out, and 3 split, and middle sliver is little compared with side sliver, and subcircular is slightly outstanding, have two the gauffer of raw glandular hair to go directly throat; 4 pieces, stamen, the last two; Ovary top is by long bristle.The flat ovoid of capsule, long 2-4mm.The florescence 4-6 month, the fruit phase 7-9 month.Record in Chinese medicine voluminous dictionary.
Close flowers and plants: this product is the herb of Stellaria plant field, Elatinaceae field Herba stellariae mediae BergiaammannioidesRoxb.ExRoth.The whole year can adopt; Clean; Dry.[nature and flavor] sweet in the mouth; Cool in nature.[function cures mainly] heat-clearing and toxic substances removing.Main urinary tract infection; Carbuncle furuncle; Stomatitis.[original shape state] annual herb, high 7-30cm.Near upright or edge up, branch is many, pale red, the glandular hair that tool is open and flat.Leaf to life, a few stockless; Slotting leaf is about 2mm, 2 drastic cracks, sliver lanceolar, tears the little tooth of shape; The narrow ellipse of blade or the lanceolar that falls, long 0.4-2cm, wide 2-8mm, there is sharp-pointed little sawtooth at edge, has undercoat below.Spend little, majority clusters in axil; The long 1-2mm of bennet; Sepal 5, narrow avette, be about 1.2mm, tip is gradually sharp; Petal 5, pale red, narrow avette, about isometric with sepal; Stamen 5; Style 5, short.Capsule is subsphaeroidal, long 1.2-2mm, and splitting is 5 lobes.I am several, minimum for seed.Florescence is close to the whole year.Record in Chinese medicine voluminous dictionary.
1 crude drug chemical constitution:
Papiliochrome II(PapiliochromeII).
Summary of the invention
The object of the invention is the deficiency overcoming background technology, pharmaceutical composition of a kind of effective treatment advanced pancreatic cancer and preparation method thereof is provided.
The present invention adopts following technical scheme to realize:
Composition and the weight portion of making the crude drug of the pharmaceutical composition of this treatment advanced pancreatic cancer are:
Papiliochrome II460-490 weight portion Herba mazi stachydifolii 6680-6700 weight portion close flowers and plants 5500-5700 weight portion.
Preferably be used for the treatment of the pharmaceutical composition of advanced pancreatic cancer, be made up of the crude drug of following weight portion:
Papiliochrome II480 weight portion Herba mazi stachydifolii 6690 weight portion close flowers and plants 5600 weight portion.
Treat a pharmaceutical composition for advanced pancreatic cancer, it is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
Treat a pharmaceutical composition for advanced pancreatic cancer, it is characterized in that the treatment advanced pancreatic cancer medicine that pharmaceutical composition and chemical drugs or Chinese medicine form.
Treat a preparation method for the pharmaceutical composition of advanced pancreatic cancer, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: papiliochrome II460-490 weight portion Herba mazi stachydifolii 6680-6700 weight portion close flowers and plants 5500-5700 weight portion;
Preparation method:
(1) papiliochrome II is got by crude drug proportioning, Herba mazi stachydifolii, close flowers and plants, mixing, with weight percent concentration 29% ethanol as solvent, extract at 37 DEG C of warm macerating, extraction time is 18 times, each extraction time is 22 hours, each solvent load is 15 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.22, filter, medicinal liquid is by HPD700 macroporous adsorptive resins, first wash with water, use weight percent concentration 44.5% alcoholic solution eluting HPD700 macroporous adsorptive resins again, collect weight percent concentration 44.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 57.5% ethanol as solvent, heating and refluxing extraction 23 times, each extraction time is 0.6 hour, each solvent load is 28 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.09, filter, medicinal liquid is by GDX-104 macroporous adsorptive resins, first wash with water, use weight percent concentration 91.5% alcoholic solution eluting GDX-104 macroporous adsorptive resins again, collect weight percent concentration 91.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Preferably treat a preparation method for the pharmaceutical composition of advanced pancreatic cancer, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: papiliochrome II480 weight portion Herba mazi stachydifolii 6690 weight portion close flowers and plants 5600 weight portion;
Preparation method:
(1) papiliochrome II is got by crude drug proportioning, Herba mazi stachydifolii, close flowers and plants, mixing, with weight percent concentration 29% ethanol as solvent, extract at 37 DEG C of warm macerating, extraction time is 18 times, each extraction time is 22 hours, each solvent load is 15 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.22, filter, medicinal liquid is by HPD700 macroporous adsorptive resins, first wash with water, use weight percent concentration 44.5% alcoholic solution eluting HPD700 macroporous adsorptive resins again, collect weight percent concentration 44.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 57.5% ethanol as solvent, heating and refluxing extraction 23 times, each extraction time is 0.6 hour, each solvent load is 28 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.09, filter, medicinal liquid is by GDX-104 macroporous adsorptive resins, first wash with water, use weight percent concentration 91.5% alcoholic solution eluting GDX-104 macroporous adsorptive resins again, collect weight percent concentration 91.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Treat a preparation method for the pharmaceutical composition of advanced pancreatic cancer, it is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
Treat a preparation method for the pharmaceutical composition of advanced pancreatic cancer, it is characterized in that pharmaceutical composition and chemical drugs or Chinese medicine form and treat advanced pancreatic cancer medicine.
Medicine composite for curing advanced pancreatic cancer is evident in efficacy.
Detailed description of the invention
Embodiment 1: pharmaceutical composition for the treatment of advanced pancreatic cancer and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of advanced pancreatic cancer are: the close flowers and plants 5600g of papiliochrome II480g Herba mazi stachydifolii 6690g;
Preparation method:
(1) papiliochrome II is got by crude drug proportioning, Herba mazi stachydifolii, close flowers and plants, mixing, with weight percent concentration 29% ethanol as solvent, extract at 37 DEG C of warm macerating, extraction time is 18 times, each extraction time is 22 hours, each solvent load is 15 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.22, filter, medicinal liquid is by HPD700 macroporous adsorptive resins, first wash with water, use weight percent concentration 44.5% alcoholic solution eluting HPD700 macroporous adsorptive resins again, collect weight percent concentration 44.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 57.5% ethanol as solvent, heating and refluxing extraction 23 times, each extraction time is 0.6 hour, each solvent load is 28 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.09, filter, medicinal liquid is by GDX-104 macroporous adsorptive resins, first wash with water, use weight percent concentration 91.5% alcoholic solution eluting GDX-104 macroporous adsorptive resins again, collect weight percent concentration 91.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Embodiment 2: pharmaceutical composition for the treatment of advanced pancreatic cancer and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of advanced pancreatic cancer are: the close flowers and plants 5500g of papiliochrome II460g Herba mazi stachydifolii 6700g;
Preparation method:
(1) papiliochrome II is got by crude drug proportioning, Herba mazi stachydifolii, close flowers and plants, mixing, with weight percent concentration 29% ethanol as solvent, extract at 37 DEG C of warm macerating, extraction time is 18 times, each extraction time is 22 hours, each solvent load is 15 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.22, filter, medicinal liquid is by HPD700 macroporous adsorptive resins, first wash with water, use weight percent concentration 44.5% alcoholic solution eluting HPD700 macroporous adsorptive resins again, collect weight percent concentration 44.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 57.5% ethanol as solvent, heating and refluxing extraction 23 times, each extraction time is 0.6 hour, each solvent load is 28 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.09, filter, medicinal liquid is by GDX-104 macroporous adsorptive resins, first wash with water, use weight percent concentration 91.5% alcoholic solution eluting GDX-104 macroporous adsorptive resins again, collect weight percent concentration 91.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Embodiment 3: pharmaceutical composition for the treatment of advanced pancreatic cancer and preparation method thereof
Composition and the weight portion of the crude drug of the pharmaceutical composition for the treatment of advanced pancreatic cancer are: the close flowers and plants 5700g of papiliochrome II490g Herba mazi stachydifolii 6680g;
Preparation method:
(1) papiliochrome II is got by crude drug proportioning, Herba mazi stachydifolii, close flowers and plants, mixing, with weight percent concentration 29% ethanol as solvent, extract at 37 DEG C of warm macerating, extraction time is 18 times, each extraction time is 22 hours, each solvent load is 15 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.22, filter, medicinal liquid is by HPD700 macroporous adsorptive resins, first wash with water, use weight percent concentration 44.5% alcoholic solution eluting HPD700 macroporous adsorptive resins again, collect weight percent concentration 44.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 57.5% ethanol as solvent, heating and refluxing extraction 23 times, each extraction time is 0.6 hour, each solvent load is 28 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.09, filter, medicinal liquid is by GDX-104 macroporous adsorptive resins, first wash with water, use weight percent concentration 91.5% alcoholic solution eluting GDX-104 macroporous adsorptive resins again, collect weight percent concentration 91.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
Embodiment 4: the preparation of tablet
Example 1 pharmaceutical composition 260g, adds starch 178g, mixing, granulates, dry, adds microcrystalline Cellulose 115g, magnesium stearate 6.5g, and mixing, is pressed into 1200, obtains medicinal composition tablets.
Embodiment 5: the preparation of capsule
Example 2 pharmaceutical composition 288g, adds starch 186g, mixing, granulates, and dry, granulate, adds appropriate magnesium stearate, and mixing, obtains medicament composition capsule by encapsulated 1400.
Embodiment 6: the preparation of drop pill
Taking polyethylene glycol 6000 239g water-bath (80 DEG C) heating boils molten, add embodiment 3 pharmaceutical composition 11g, stirring, is coolant with liquid paraffin, puts in glass tubing (4*80cm), chilling temperature is 2 DEG C, drip internal-and external diameter is 7.0/2.0 (mm/mm), and drip is 3.5cm apart from liquid level, drips speed with per minute 55 for optimum condition, blot the condensing agent on drop pill surface with cotton, obtain medicament composition dropping pills.
Experimental example 1: the experimental study for the treatment of advanced pancreatic cancer
1 clinical data
1.1 case inclusive criterias
The diagnosis related standards met in " common cancer diagnosis and treatment specification " is diagnosed as cancer of pancreas; Age 18-70 year; Karnofsky (Ka Shi) Ping Fen 60 points; More than expection >3 life cycle month; Routine blood test, renal function, liver function and every biochemical indicator are normal; Within nearly more than 1 month, do not accept other antineoplastons; Compliance is good , , phase patient.
1.2 case exclusion standards
The person that do not meet inclusive criteria; Trimester of pregnancy or women breast-feeding their children; Organic lesion and the hemopoietic function of bone marrow obstacle persons such as the serious heart, liver, kidney, brain; The psychotic of cognitive competence forfeiture or psychological problem; Allergic constitution and multi-medicament allergy sufferers.
1.3 physical data
26 examples are included case in and are city's Patients during Hospital Ward in June ,-2011 in May, 2009.Comprise man 13 example, female 13 example; The oldest 66 years old, minimum 30 years old, the median age 55.4 years old; phase 5 example, phase 15 example, phase 6 example.Random digits table is adopted to be divided into chemotherapy group 13 example and pharmaceutical composition+chemotherapy group 13 example.Before treatment, baseline analysis compares two groups of sexes, age, Ka Shi scoring and clinical stages etc. there are no significant difference (P>0.05), has comparability.
2 methods
2.1 Therapeutic Method
Chemotherapy group: gemcitabine 1000mg/m 2within 1st day and the 8th day, add quiet more than the 30min of normal saline dilution.This scheme every 21 days is 1 cycle, 2 cycles of continuous chemotherapy.
Pharmaceutical composition+chemotherapy group: chemotherapy regimen and the course for the treatment of same chemotherapy group, at chemotherapy simultaneously combination of oral medication (embodiment 1 pharmaceutical composition lot number 20081120), every day 3 times, each 0.6g, until 2 chemotherapy cycles terminate.
2.2 observational technique
Therapeutic evaluation is carried out after 2 chemotherapy cycles.
2.2.1 the objective curative effect of solid tumor
Adopt WHO about the efficacy assessment standard for the treatment of of solid tumors.Complete incidence graph (CR): visible pathological changes disappeared completely, more than 1 month; Partial rcsponse (PR): mass reduction (single pathological changes tumor area refers to the product in lump two maximum perpendicular footpaths, and multiple lump refers to two maximum perpendicular footpath sum of products) more than 50%, many 1 month of time; Stable (NC): mass reduction is not as good as 50% or increase more than 25%; Progress (PD): one or more pathological changes increases more than 25% or occur new pathological changes.Clinical benefit rate is calculated according to CR+PR+NC.
2.2.2 change of serum C A19-9 changes
After treatment, serum CA 19-9 levels is down to normal is complete incidence graph (CR); Decline >25% is partial rcsponse (PR); Decline <25% and increase <25% for stable (NC); Increase >50% for progress (PD).
2.2.3 physical status assessment
Quality of life assessment is carried out according to Ka Shi scoring (Karnofsky).Ka Shi standards of grading: before and after treatment, scoring raising 10 is divided into raising; Reduce 10 and be divided into reduction; Be stable without increase and decrease person.According to raising and stability Calculation benefit factor.
2.2.4 clinical symptoms improves evaluation
Clinical symptoms improves situation, asymptomaticly comments 0 point, and have symptom to comment 2 points, remarkable 4 points of symptom, the summation of each individual scores is called clinical symptoms integration.
2.2.5 toxicity is observed
Peripheral blood leucocyte, erythrocyte, hemoglobin, platelet and Liver and kidney function situation of change before and after treatment, toxicity evaluation is according to " cancer therapy drug acute and subacute toxicity standard " evaluation in " cancer therapy drug guideline of clinical investigations ".
2.2.6 statistical method
Adopt SPSS11.5 statistical software, enumeration data adopts X 2 test, and measurement data adopts t inspection, and ranked data adopt rank test.
3 results
The objective comparitive study of 3.1 solid tumor
The objective comparitive study no difference of science of statistics of solid tumor CR, PR, NC, PD after two groups of treatments, P>0.05.Clinical benefit rate pharmaceutical composition+chemotherapy group (100%) is better than chemotherapy group (76.92%), has significant difference, P<0.05, in table 1.
Objective comparitive study/the example (%) of table 1 liang group object tumor
Group n CR PR NC PD CR+PR+NC
Chemotherapy group 13 0 4 6 3 10（76.92）
Pharmaceutical composition+chemotherapy group 13 1 9 3 0 13（100）*
Note: compare with chemotherapy group, * P<0.05.
3.2 change of serum C A19-9 changes are compared
Pharmaceutical composition+chemotherapy group curative effect is better than chemotherapy group, has significant difference (P<0.05), in table 2.
After table 2 liang group treatment ,/example (%) is compared in change of serum C A19-9 change
Note: through rank test, compares with chemotherapy group, * P<0.05.
3.3 physical situation scorings
After chemotherapy group treatment, comparatively treatment is front improves 1 example, stablizes 6 examples; Pharmaceutical composition+chemotherapy group improves 4 examples, stablizes 8 examples; Two groups of benefit factors are respectively 53.85%, 92.31%, and the equal significance of difference, P<0.05, in table 3.
/ example (%) is compared in a table 3 liang group Ka Shi scoring
Group n Improve Stable Reduce Improve+stable
Chemotherapy group 13 1(7.69) 6(46.15) 6(46.15) 7(53.85)
Pharmaceutical composition+chemotherapy group 13 4(30.77)* 8(61.54)* 1(7.69)* 12(92.31)*#
Note: through rank test, compares with chemotherapy group, * P<0.05; Through X 2 test, compare with chemotherapy group, #P<0.05.
3.4 clinical symptoms improve evaluation
Result display pharmaceutical composition+chemotherapy group compare with chemotherapy group clinical symptoms improve be mainly manifested in suffer from abdominal pain, loss of appetite, Mental fatigue, insomnia aspect, all have significance through statistical test difference, P<0.05, in table 4.
Table 4 clinical symptoms integral contrast (x ± s)
Clinical symptoms Chemotherapy group/point Pharmaceutical composition+chemotherapy group/points 6-->
Stomachache 2.37±0.35 1.76±0.16*
Loss of appetite 2.45±0.78 1.79±0.96*
Mental fatigue 2.56±1.04 1.69±0.81*
Insomnia 2.46±1.22 1.58±0.92*
Note: through t inspection, compare with chemotherapy group, * P<0.05.
3.5 toxicities are observed
After two groups of treatments, peripheral blood leucocyte (WBC), erythrocyte (RBC), hemoglobin (HGB), platelet (PLT) and liver (ALT), renal function (Cr) all do not occur level toxicity of chemotherapy, two groups of WBC toxic reaction tool significances, P<0.05, other haematics toxicities and Liver and kidney function toxicity ratio comparatively no difference of science of statistics, P>0.05.
Result shows, pharmaceutical composition have delay solid tumor increase, reduce CA19-9, improve clinical symptoms, improve patients ' life quality, alleviate chemotherapy and cause leukopenic toxicity, good clinical benefit reponse is demonstrated to advanced pancreatic cancer patient.

Claims (8)

1. treat a pharmaceutical composition for advanced pancreatic cancer, it is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:
Papiliochrome II460-490 weight portion Herba mazi stachydifolii 6680-6700 weight portion close flowers and plants 5500-5700 weight portion.
2. a kind of pharmaceutical composition for the treatment of advanced pancreatic cancer according to claim 1, is characterized in that the composition of the crude drug making this pharmaceutical composition and weight portion are:
Papiliochrome II480 weight portion Herba mazi stachydifolii 6690 weight portion close flowers and plants 5600 weight portion.
3. a kind of pharmaceutical composition for the treatment of advanced pancreatic cancer according to claim 1, is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
4. a kind of pharmaceutical composition for the treatment of advanced pancreatic cancer according to claim 1, is characterized in that the treatment advanced pancreatic cancer medicine that pharmaceutical composition and chemical drugs or Chinese medicine form.
5. treat a preparation method for the pharmaceutical composition of advanced pancreatic cancer, it is characterized in that preparing as follows:
The composition of crude drug and weight portion are: papiliochrome II460-490 weight portion Herba mazi stachydifolii 6680-6700 weight portion close flowers and plants 5500-5700 weight portion;
Preparation method:
(1) papiliochrome II is got by crude drug proportioning, Herba mazi stachydifolii, close flowers and plants, mixing, with weight percent concentration 29% ethanol as solvent, extract at 37 DEG C of warm macerating, extraction time is 18 times, each extraction time is 22 hours, each solvent load is 15 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.22, filter, medicinal liquid is by HPD700 macroporous adsorptive resins, first wash with water, use weight percent concentration 44.5% alcoholic solution eluting HPD700 macroporous adsorptive resins again, collect weight percent concentration 44.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 57.5% ethanol as solvent, heating and refluxing extraction 23 times, each extraction time is 0.6 hour, each solvent load is 28 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.09, filter, medicinal liquid is by GDX-104 macroporous adsorptive resins, first wash with water, use weight percent concentration 91.5% alcoholic solution eluting GDX-104 macroporous adsorptive resins again, collect weight percent concentration 91.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
6. a kind of preparation method for the treatment of the pharmaceutical composition of advanced pancreatic cancer according to claim 5, is characterized in that preparing as follows:
The composition of crude drug and weight portion are: papiliochrome II480 weight portion Herba mazi stachydifolii 6690 weight portion close flowers and plants 5600 weight portion;
Preparation method:
(1) papiliochrome II is got by crude drug proportioning, Herba mazi stachydifolii, close flowers and plants, mixing, with weight percent concentration 29% ethanol as solvent, extract at 37 DEG C of warm macerating, extraction time is 18 times, each extraction time is 22 hours, each solvent load is 15 times of crude drug gross weight, filter, obtain medicinal residues A and extracting solution A, extracting solution A reclaims ethanol, be concentrated into relative density 1.22, filter, medicinal liquid is by HPD700 macroporous adsorptive resins, first wash with water, use weight percent concentration 44.5% alcoholic solution eluting HPD700 macroporous adsorptive resins again, collect weight percent concentration 44.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract A,
(2) step (1) medicinal residues A is got, with weight percent concentration 57.5% ethanol as solvent, heating and refluxing extraction 23 times, each extraction time is 0.6 hour, each solvent load is 28 times of medicinal residues A weight, filter, obtain medicinal residues B and extracting solution B, extracting solution B reclaims ethanol, be concentrated into relative density 1.09, filter, medicinal liquid is by GDX-104 macroporous adsorptive resins, first wash with water, use weight percent concentration 91.5% alcoholic solution eluting GDX-104 macroporous adsorptive resins again, collect weight percent concentration 91.5% ethanol elution, reclaim ethanol, concentrate drying, obtain extract B,
(3) by extract A and extract B mixing, pharmaceutical composition is obtained.
7. a kind of preparation method for the treatment of the pharmaceutical composition of advanced pancreatic cancer according to claim 5, is characterized in that pharmaceutical composition can adopt the conventional method of galenic pharmacy to be prepared into tablet or capsule or drop pill.
8. a kind of preparation method for the treatment of the pharmaceutical composition of advanced pancreatic cancer according to claim 5, is characterized in that pharmaceutical composition and chemical drugs or Chinese medicine form and treats advanced pancreatic cancer medicine.
CN201610047066.5A 2016-01-25 2016-01-25 Medicine composition for treating middle and advanced pancreatic cancer Withdrawn CN105535227A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610047066.5A CN105535227A (en) 2016-01-25 2016-01-25 Medicine composition for treating middle and advanced pancreatic cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610047066.5A CN105535227A (en) 2016-01-25 2016-01-25 Medicine composition for treating middle and advanced pancreatic cancer

Publications (1)

Publication Number Publication Date
CN105535227A true CN105535227A (en) 2016-05-04

Family

ID=55815138

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610047066.5A Withdrawn CN105535227A (en) 2016-01-25 2016-01-25 Medicine composition for treating middle and advanced pancreatic cancer

Country Status (1)

Country Link
CN (1) CN105535227A (en)

Similar Documents

Publication Publication Date Title
CN106668348A (en) Pharmaceutical composition for treating diabetic retinopathy
CN106038637A (en) Pharmaceutical composition for treating breast cancer
CN105560608A (en) Pharmaceutical composition for treating lung cancer
CN105535095A (en) Medicine composition for treating liver ascites
CN105287921A (en) Medicinal composition for treating gastric cancer and preparation method thereof
CN105535227A (en) Medicine composition for treating middle and advanced pancreatic cancer
CN105998697A (en) Medicine composition for treating esophagus cancer
CN105560299A (en) Medicine composition for treating middle and advanced stage pancreatic carcinoma
CN105616987A (en) Pharmaceutical composition for preventing and treating prostatic hyperplasia and preparation method thereof
CN106074736A (en) A kind of pharmaceutical composition treating cerebral thrombosis and preparation method thereof
CN105327009A (en) Medicinal composition for treating malignant tumor and preparation method thereof
CN105687278A (en) Pharmaceutical composition for treating middle and advanced stage lung cancer
CN106138175A (en) The pharmaceutical composition for the treatment of Advanced Colon Cancer
CN106038638A (en) Drug compound for preventing and treating breast cancer and preparation method thereof
CN106109550A (en) Pharmaceutical composition for the treatment of colon cancer and preparation method thereof
CN106728474A (en) Treat the pharmaceutical composition of thyroid disease
CN106109522A (en) Prevent and treat the pharmaceutical composition of cervical cancer
CN106581102A (en) Pharmaceutical composition for treatment of uterine myoma
CN106581433A (en) Medicine composition for preventing and treating periodontitis
CN106728628A (en) Treat the pharmaceutical composition of canker sore
CN106539833A (en) One kind treats colpitic pharmaceutical composition
CN106620064A (en) Medicinal composition for treating undifferentiated arthritis and preparation method of medicinal composition
CN106109606A (en) A kind of pharmaceutical composition treating colon cancer and preparation method thereof
CN106581263A (en) Pharmaceutical composition for treating lumbar disc herniation and preparation method thereof
CN106511588A (en) Pharmaceutical composition for treating colpitis

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20160504